Celldex Announces Upcoming Oral Presentation on CDX-301 at the American Society for Blood and Marrow Transplantation 2013 BMT

Celldex Announces Upcoming Oral Presentation on CDX-301 at the American
Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings

NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc.
(Nasdaq:CLDX) today announced that Michael Yellin, MD, Vice President of
Clinical Science, will present final results from a Phase 1 trial of CDX-301
(rhuFlt3L) in healthy volunteers in an oral presentation at the American
Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings. The
presentation will be held on Wednesday, February 13, 2013 at 4:45 pm MST (6:45
pm EST) at the Salt Palace Convention Center in Salt Lake City, Utah. The
Company will issue a press release outlining the results of the presentation
before market open on Thursday, February 14, 2013. The Company previously
announced that it plans to initiate a pilot study in hematopoietic stem cell
transplant by year end 2013.

CDX-301 or Flt3L is a potent cytokine that stimulates the expansion and
differentiation of hematopoietic progenitor and stem cells. Flt3L has
demonstrated a unique capacity to increase the number of circulating dendritic
cells in both laboratory and clinical studies. In addition, Flt3L has shown
impressive results in models of cancer, infectious diseases and
inflammatory/autoimmune diseases. Celldex believes this ligand may hold
significant opportunity for synergistic development in combination with other
molecules.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is the first antibody-based combination immunotherapy
company. Celldex has a pipeline of drug candidates in development for the
treatment of cancer and other difficult-to-treat diseases based on its
antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI
Platform is a complementary portfolio of monoclonal antibodies,
antibody-targeted vaccines and immunomodulators used in optimal combinations
to create novel disease-specific drug candidates.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995, including those related to the Company's strategic focus and the future
development and commercialization of CDX-011 or any of our other drug
candidates, including rindopepimut (CDX-110), CDX-1135 (formerly TP10),
CDX-1401, CDX-1127, CDX-301, Belinostat and any future action we or the FDA
(or any other regulator) might take with respect to regulatory approvals.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance or events.
Although management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such expectations will
prove to be correct and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties,
including, but not limited to, future actions that the FDA and other
regulators might take or not take with respect to CDX-011 or any drug
candidate, the market for CDX-011 or any other drug candidate or assay, future
clinical testing which will be necessary before FDA approval could be sought,
our ability to obtain additional capital on acceptable terms, or at all,
including the additional capital which will be necessary to complete the
clinical trials that we initiated in 2012 and plan to initiate in 2013; our
ability to adapt APC Targeting TechnologyTM to develop new, safe and effective
vaccines against oncology and infectious disease indications; our ability to
successfully complete product research and further development of our
programs; the uncertainties inherent in clinical testing; our limited
experience in bringing programs through Phase 3 clinical trials; our ability
to manage research and development efforts for multiple products at varying
stages of development; the timing, cost and uncertainty of obtaining
regulatory approvals; the failure of the market for the Company's programs to
continue to develop; our limited cash reserves and our ability to obtain
additional capital on acceptable terms, or at all; our ability to protect the
Company's intellectual property; the loss of any executive officers or key
personnel or consultants; competition; changes in the regulatory landscape or
the imposition of regulations that affect the Company's products; and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission, including the Company's Form 10-K for the fiscal year
ended December 31, 2011, and its Forms 10-Q and 8-K.

All forward-looking statements are expressly qualified in their entirety by
this cautionary notice. You are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release.
We have no obligation, and expressly disclaim any obligation, to update,
revise or correct any of the forward-looking statements, whether as a result
of new information, future events or otherwise.

CONTACT: Sarah Cavanaugh
         Vice President of IR & Corp Communications
         Celldex Therapeutics, Inc.
         (781) 433-3161
         scavanaugh@celldextherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.